FindTrial
Sign In

Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)

Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030898
Enrollment
Unknown
Registered
2020-03-16
Start date
2020-01-27
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Population under risk:Chushifangyi prescription

Sponsors

The affiliated Hospital to Changchun University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Vulnerable and high risk groups such as health care workers and non health care workers in health care settings. 2019-ncov.

Exclusion criteria

Exclusion criteria: 1. A pregnant or lactating woman; 2. With other major diseases, such as serious heart, lung, liver, kidney damage or psychiatric patients. Participants should not take part in the study under any of the above circumstances. The Research Hospital and the applicant unit will not bear the responsibility if they intentionally conceal the medical history and medication history.

Design outcomes

Primary

MeasureTime frame
Confirmed 2019-ncov pneumonia;—

Secondary

MeasureTime frame
Symptom Scale of Traditional Chinese Medicine;Fatigue Scale-14 (FS-14);—

Countries

China

Contacts

Public ContactWang Tan

Affiliated Hospital of Changchun University of Traditional Chinese Medicine

Wangtan215@sina.com+86 13756858523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026